RT Journal Article
SR Electronic
T1 Mitigating the psychological impacts of COVID-19 restrictions on older people: The UK Behavioural Activation in Social Isolation (BASIL+) COVID-19 Urgent Public Health (UPH) trial and living systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.13.23291329
DO 10.1101/2023.06.13.23291329
A1 Gilbody, Simon
A1 Littlewood, Elizabeth
A1 McMillan, Dean
A1 Atha, Lucy
A1 Bailey, Della
A1 Baird, Kalpita
A1 Brady, Samantha
A1 Burke, Lauren
A1 Chew-Graham, Carolyn A.
A1 Coventry, Peter
A1 Crosland, Suzanne
A1 Fairhurst, Caroline
A1 Henry, Andrew
A1 Hollingsworth, Kelly
A1 Newbronner, Elizabeth
A1 Ryde, Eloise
A1 Shearsmith, Leanne
A1 Wang, Han-I
A1 Webster, Judith
A1 Woodhouse, Rebecca
A1 Clegg, Andrew
A1 Dexter-Smith, Sarah
A1 Gentry, Tom
A1 Hewitt, Catherine
A1 Hill, Andrew
A1 Lovell, Karina
A1 Sloan, Claire
A1 Traviss-Turner, Gemma
A1 Pratt, Steven
A1 Ekers, David
YR 2023
UL http://medrxiv.org/content/early/2023/06/18/2023.06.13.23291329.abstract
AB Background Older adults were more likely to be socially isolated during the COVID-19 pandemic, with risk of depression and loneliness. Behavioural Activation (BA) could feasibly maintain mental health in the face of COVID isolation.Methods We undertook a multicentre randomised controlled trial [BASIL+ ISRCTN63034289] of BA to mitigate depression and loneliness among older people. BA was offered by telephone to intervention participants (n=218). Control participants received usual care, with existing COVID wellbeing resources (n=217).Findings Participants engaged with 5.2 (SD 2.9) of 8 remote BA sessions. Adjusted mean difference (AMD) for depression (PHQ-9) at 3 months [primary outcome] was -1.65 (95% CI -2.54 to -0.75, p<0.001). There was an effect for BA on emotional loneliness at 3 months (AMD -0.37, 95% CI -0.68 to -0.06, p=0.02), but not social loneliness (AMD -0.05, 95% CI -0.33 to 0.23, p=0.72). Other secondary outcomes at 3 months were anxiety (GAD-7: AMD -0.67, 95% CI -1.43 to 0.09, p=0.08) and quality of life (SF12 mental component: AMD 1.99, 95% CI 0.22 to 3.76, p=0.03; physical component: AMD - 0.50, 95% CI -2.14 to 1.10, p=0.53).BASIL+ trial results were incorporated into a living systematic review [PROSPERO CRD42021298788], and we found strong evidence of an impact of behavioural and/or cognitive strategies on depression [random effects pooled standardised mean difference -0.32, 95% CI -0.48 to -0.16, 10 studies, n=1,210 participants] and loneliness [random effects pooled standardised mean difference -0.44, 95%CI -0.64 to -0.24, 13 studies, n=1,421 participants] in the short-term (<6 months).Interpretation BA is an effective intervention that reduces depression and some aspects of loneliness in the short term. This adds to the range of strategies to improve population mental health, particularly among older adults with multiple long-term conditions. These results will be helpful to policy makers in preventing depression and loneliness beyond the pandemic.Funding NIHR RP-PG-0217-20006Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN63034289Clinical Protocols https://www.isrctn.com/editorial/retrieveFile/144ca2e6-ddf8-4d0c-803b-6273b68a7f20/39406 Funding StatementThis project was funded by the NIHR Programme Grants for Applied Research (PGfAR) programme (RP-PG-0217-20006). The scope of our pre-existing research into multimorbidity in older people was extended at the outset of the COVID-19 pandemic with the agreement of the funder to consider depression and loneliness in this vulnerable group. The NIHR PGfAR programme had no role in the writing of this manuscript or the decision to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BASIL+ trial received ethical approval from a Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8018; leedswest.rec@hra.nhs.uk) on 11/12/2021 (REC Ref: 20/YH/0347). The sponsor for BASIL+ was Tees, Esk and Wear Valleys NHS Foundation Trust.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymised data will be made available upon reasonable request, which must include a protocol and statistical analysis plan and not be in conflict with our prespecified publication plan, consistent with our data sharing policy (available on request from SG). The BASIL research collective is especially keen that the BASIL data contributes to prospective meta-analyses and individual patient data meta-analyses. Requests for data sharing will be considered by SG and the independent trial steering and data monitoring committee.